From Tom Sullivan’s Policy and Medicine blog: cell spy Tom Sullivan cites a recent article on industry support of CME in Clinical Pharmacology & Therapeutics and elaborates on its argument that “…some of healthcare’s greatest contributions have originated from industry-sponsored science,” and says that to eliminate the industry now would be detrimental to patients. Read […]
Read more